Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera Protein, CF

Catalog # Availability Size / Price Qty
2078-T4-050
Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera Protein Binding Activity
1 Image
Product Details
Citations (1)
FAQs
Supplemental Products
Reviews

Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera Protein, CF Summary

Product Specifications

Purity
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its binding ability in a functional ELISA. When Recombinant Human Angiopoietin-like Protein 5/ANGPTL5 (Catalog # 6675-AN) is coated at 4 μg/mL, Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera binds with a typical ED50 of 0.15-0.9 μg/mL. Measured by its ability to support the adhesion of HSB2 human peripheral blood acute lymphoblastic leukemia cells. Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera immobilized at 35 µg/mL, 100 µL/well, will mediate >40% HSB-2 cell adhesion (105 cells/well).
Source
Mouse myeloma cell line, NS0-derived human LILRB2/CD85d/ILT4 protein
Human LILRB2/CD85d/ILT4
(Gly24-His458)
Accession # AAH36827.1
IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus
Accession #
N-terminal Sequence
Analysis
Gly24
Structure / Form
Disulfide-linked homodimer
Predicted Molecular Mass
73.9 kDa (monomer)
SDS-PAGE
94-100 kDa, reducing conditions

Product Datasheets

You must select a language.

x

2078-T4

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

2078-T4

Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Binding Activity Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera Protein Binding Activity View Larger

Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera (Catalog # 2078-T4) supports the adhesion of HSB2 human peripheral blood acute lymphoblastic leukemia cells. Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera immobilized at 35 µg/mL, 100 µL/well, will mediate >40% HSB-2 cell adhesion (105cells/well).

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: LILRB2/CD85d/ILT4

The immunoglobulin-like transcript (ILT) comprise a family of activating and inhibitory type immunoreceptors whose genes are located in the same locus that encodes killer cell Ig-like receptors (KIR) (1-3). ILT4, also known as LIR-2 and LILRB2, is a type I transmembrane protein expressed primarily on monocytes and dendritic cells (DC) (4). Human ILT4 is produced as a 598 amino acid (aa) precursor including a 21 aa signal sequence, a 440 aa extracellular domain (ECD), a 21 aa transmembrane segment, and a 116 aa cytoplasmic domain. The ECD contains four Ig-like domains, and the cytoplasmic domain contains three immunoreceptor tyrosine-based inhibitory motifs (ITIM) (5). The ECD of human ILT4 shares 76% aa identity with chimpanzee ILT4 and 74%, 81%, 33%, 52%, 77%, 61%, and 64 % aa identity with human ILT1, 2, 3, 5, 6, 7, and 8, respectively. ILT4 binds to classical MHC I proteins as well as the non-classical HLA-G1 and HLA-F molecules (5-9). It competes with CD8 alpha for MHC I binding but does not compete with KIR2DL1 (7). Ligation of ILT4 induces Tyr phosphorylation within its cytoplasmic ITIMs, a requirement for association with SHP-1 (4, 6). Activation of ILT4 inhibits signaling through Fc gamma RI (4) and Fc epsilon RI (6) and causes DC to become tolerogenic by down-regulation of co‑stimulatory molecules (10, 11). ILT4 mediates tolerogenic DC‑induced CD4+ T cell energy in vitro and in vivo (10-12).

References
  1. Suciu-Foca, N. et al. (2005) Int. Immunopharmacol. 5:7. 
  2. Hofmeister, V. and E.H. Weiss (2003) Semin. Canc. Biol. 13:317. 
  3. Hunt, J.S. et al. (2005) FASEB J. 19:681. 
  4. Finger, N.A. et al. (1998) Eur. J. Immunol. 28:3423. 
  5. Borges, L. et al. (1997) J. Immunol. 159:5192. 
  6. Colonna, M. et al. (1998) J. Immunol. 160:3096. 
  7. Shiroishi, M. et al. (2003) Proc. Natl. Acad. Sci. 100:8856.
  8. Lepin, E.J.M. et al. (2000) Eur. J. Immunol. 30:3552.
  9. Allen, R.L. et al. (2001) J. Immunol. 167:5543.
  10. Chang, C.C. et al. (2002) Nat. Immunol. 3:237.
  11. Ristich, V. et al. (2005) Eur. J. Immunol. 35:1133.
  12. Manavalan, J.S. et al. (2003) Transpl. Immunol. 11:245.
Long Name
Leukocyte Immunoglobulin-like Receptor, Subfamily B (with TM and ITIM Domains), Member 5
Entrez Gene IDs
10288 (Human)
Alternate Names
CD85 antigen-like family member D; CD85d antigen; CD85d; Ig-like transcript 4; ILT4; ILT-4; ILT4CD85d; Immunoglobulin-like transcript 4; Leukocyte immunoglobulin-like receptor 2; leukocyte immunoglobulin-like receptor subfamily B member 2 soluble isoform; leukocyte immunoglobulin-like receptor subfamily B member 2; leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains); LILRB2; LIR2; LIR2CD85D; LIR-2subfamily A (with TM domain), member 6; member 2; MIR10; MIR10LILRA6; Monocyte/macrophage immunoglobulin-like receptor 10

Citation for Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera Protein, CF

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

1 Citation: Showing 1 - 1

  1. A viral CTL escape mutation leading to immunoglobulin-like transcript 4-mediated functional inhibition of myelomonocytic cells.
    Authors: Lichterfeld M, Kavanagh DG, Williams KL, Moza B, Mui SK, Miura T, Sivamurthy R, Allgaier R, Pereyra F, Trocha A, Feeney M, Gandhi RT, Rosenberg ES, Altfeld M, Allen TM, Allen R, Walker BD, Sundberg EJ, Yu XG
    J. Exp. Med., 2007-11-19;204(12):2813-24.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Surface Plasmon Resonance

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs
Loading...

Reviews for Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera Protein, CF

There are currently no reviews for this product. Be the first to review Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera Protein, CF and earn rewards!

Have you used Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera Protein, CF?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review